November 17, 2017
November 16, 2017
Retrotope initiates second patient for Compassionate Use of RT001 for an ultrarare genetic neurological disease, Infantile Neuroaxonal Dystrophy.
October 4, 2017
Zavante Therapeutics Presents Additional Clinical and Microbiologic Data From ZOLYD™ Phase 2/3 Trial at ID Week 2017
September 8, 2017
Zavante Therapeutics Announces Agreement With NIAID To Assess ZOLYD™ For Lower Respiratory Tract Infections
Oncternal Therapeutics: UCSD cancer clinical trial gets $18.2 million
June 6, 2017
Zavante Therapeutics Presents Positive Results From NIH-Sponsored ZOLYD™ Phase 1 Trial At ASM Microbe 2017 Meeting
May 15, 2017
Genoa Pharmaceuticals Secures $62 Million Series A Financing, Adds to Leadership Team
May 8, 2017
Retrotope Chairman, Dr. Harry J. Saal, highlights the ideas and concepts behind Retrotope’s technology at TEDxPaloAlto
April 5, 2017
Zavante Therapeutics’ ZOLYD™ Met Primary Endpoint in Pivotal ZEUS Study for Treatment of Complicated Urinary Tract Infections
February 22, 2017